Prime Medicine (PRME) Capital Expenditures (2021 - 2026)

Prime Medicine (PRME) has 6 years of Capital Expenditures data on file, last reported at $214000.0 in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures fell 91.16% year-over-year to $214000.0; the trailing twelve-month figure through Mar 2026 stood at -$2.1 million (down 267.25% YoY), and the FY2025 full-year result was $114000.0, down 90.12% from the prior year.
• Capital Expenditures for Q1 2026 stood at $214000.0, up from -$4.1 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $6.2 million in Q3 2023 and bottomed at -$4.1 million in Q4 2025.
• The 5-year median for Capital Expenditures is $895000.0 (2022), against an average of $657352.9.
• Peak annual rise in Capital Expenditures reached 1777.46% in 2025, while the deepest fall reached 495.69% in 2025.
• A 5-year view of Capital Expenditures shows it stood at $99000.0 in 2022, then surged by 1758.59% to $1.8 million in 2023, then plunged by 43.32% to $1.0 million in 2024, then sank by 495.69% to -$4.1 million in 2025, then soared by 105.19% to $214000.0 in 2026.
• The last three Capital Expenditures figures came in at $214000.0 (Q1 2026), -$4.1 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.

Peer Comparison